Related Experiment Video
Updated: May 29, 2026
Evaluation of the Feasibility, Safety, and Accuracy of an Intraoperative High-intensity Focused Ultrasound Device for Treating Liver Metastases
Published on: January 9, 2019
[HIFU for prostate cancer in patients with a history of severe colorectal disease]
A Mitach1, S Crouzet, L Poissonier
1Service d'urologie et chirurgie de la transplantation, hôpital Édouard-Herriot, Lyon, France. mitach2@yahoo.fr
Objectives:
To report the functional and oncological outcomes of HIFU for prostate cancer in patients with a history of severe colorectal disease.
Methods:
Between 2002 and 2009, 14 patients with a history of severe colorectal disease (cancer, lymphoma, inflammatory bowel diseases [IBD]) were treated with HIFU as a primary care option for localized prostate cancer.
Results:
Mean age was 65.8 ± 6.1 years. Mean time between colorectal disease treatment and HIFU was 10.6 ± 6.8 years. The mean Prostate Specific Antigen (PSA) before HIFU was 12.1 ng/mL (4.5-55). Gleason score was inferior or equal to 6 in four patients (28.6%), equal to 7 in nine patients (64.3%) and superior or equal to 8 in one patient (7.1%). The mean prostate volume before HIFU was 22.1 ± 11.7 mL. The number of HIFU sessions per patient was 1.35. The mean nadir PSA was 0.61 ± 0.82 ng/mL. Systematic control biopsies were negative in seven patients (50%). Mean follow-up was 22 months with a 35.7% complication rate (three erectile dysfunctions, two urinary stress incontinences). No recto-urethral fistula occurred.
Conclusion:
HIFU was an interesting therapy for patients with a history of colorectal disease for whom regular treatment was challenging or non feasible.
